Improvement of Quality of Life of Hemophiliac Patients Clinical Trial
Official title:
Assessment of Quality of Life in Hemophiliac Patients
Hemophilia is an X-linked congenital bleeding disorder caused by deficiency of coagulation
factor VIII (in hemophilia A) or factor IX (in hemophilia B).
The deficiency is the result of mutations of the respective clotting factor genes.
Hemophilia is rare, with only about 1 instance in every 10,000 births (or 1 in 5,000 male
births) for hemophilia A and 1 in 50,000 births for hemophilia B.
According to the World Federation of Hemophilia, 400 000 people worldwide & 5,307 people in
Egypt are suffering from hemophilia.
Hemophilia A is more common than hemophilia B, representing 80-85 % of the total hemophilia
population.
Signs and symptoms of hemophilia vary according to the level of clotting factors, mild,
moderate and sever.
- Unexplained excessive bleeding from cuts or injuries
- Epistaxis without a known cause
- Many large or deep bruises
- Hamoarthritis
- Hematuria and Melena.
- Intracranial hemorrhage and death
- In infants, unexplained irritability
it is subjective representation of health, including not only physical,mental and social,
but also emotional and everyday life dimensions in terms of well-being. Several definitions
of QoL have been provided, the definition of the WHO viewing QoL as 'individuals perceptions
of their position in life in the context of culture and value systems in which they live and
in relation to their goals, expectation standards and concerns'
;